{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["De Gregorio E"],"funding":["Fondazione per la Ricerca sulla Fibrosi Cistica"],"pagination":["E362"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7344813"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(6)"],"pubmed_abstract":["Staphylococcus aureus is one of the major causes of hospital- and community-associated bacterial infections throughout the world, which are difficult to treat due to the rising number of drug-resistant strains. New molecules displaying potent activity against this bacterium are urgently needed. In this study, d- and l-deoxynojirimycin (DNJ) and a small library of their N-alkyl derivatives were screened against S. aureus ATCC 29213, with the aim to identify novel candidates with inhibitory potential. Among them, N-nonyloxypentyl-l-DNJ (l-NPDNJ) proved to be the most active compound against S. aureus ATCC 29213 and its clinical isolates, with the minimum inhibitory concentration (MIC) value of 128 μg/mL. l-NPDNJ also displayed an additive effect with gentamicin and oxacillin against the gent"],"journal":["Antibiotics (Basel, Switzerland)"],"pubmed_title":["N-Nonyloxypentyl-l-Deoxynojirimycin Inhibits Growth, Biofilm Formation and Virulence Factors Expression of Staphylococcus aureus."],"pmcid":["PMC7344813"],"funding_grant_id":["FFC #20/2019"],"pubmed_authors":["Iula VD","Esposito A","Migliaccio A","Zarrilli R","De Gregorio E","De Fenza M","D'Alonzo D","Guaragna A","Vollaro A"],"additional_accession":[]},"is_claimable":false,"name":"N-Nonyloxypentyl-l-Deoxynojirimycin Inhibits Growth, Biofilm Formation and Virulence Factors Expression of Staphylococcus aureus.","description":"Staphylococcus aureus is one of the major causes of hospital- and community-associated bacterial infections throughout the world, which are difficult to treat due to the rising number of drug-resistant strains. New molecules displaying potent activity against this bacterium are urgently needed. In this study, d- and l-deoxynojirimycin (DNJ) and a small library of their N-alkyl derivatives were screened against S. aureus ATCC 29213, with the aim to identify novel candidates with inhibitory potential. Among them, N-nonyloxypentyl-l-DNJ (l-NPDNJ) proved to be the most active compound against S. aureus ATCC 29213 and its clinical isolates, with the minimum inhibitory concentration (MIC) value of 128 μg/mL. l-NPDNJ also displayed an additive effect with gentamicin and oxacillin against the gent","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jun","modification":"2025-04-22T19:37:11.35Z","creation":"2025-04-06T02:47:26.12Z"},"accession":"S-EPMC7344813","cross_references":{"pubmed":["32604791"],"doi":["10.3390/antibiotics9060362"]}}